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Cisplatin (CDDP), an anticancer drug, induces remarkable toxicity in the kidneys of animals and humans and it has been well
documented that reactive oxygen species and the renal antioxidant system are strongly involved in acute renal damage induced by
CDDP. The aim of the present study was to investigate whether or not the renal antioxidant system plays also an important role
in chronic renal damage induced by repeated doses of CDDP (1mg/kg intraperitoneally twice weekly during 10 weeks in rats).
In order to elucidate it, serum creatinine and urea levels, renal glutathione and thiobarbituric acid-reactive substances (TBARS)
content, as well as renal superoxide dismutase and glutathione peroxidase activities were measured in the kidney homogenates of
chronically CDDP-treated rats and additionally histological studies were performed in the rat kidneys. The chronic treatment with
CDDP induced a signiﬁcant increase in creatinine and urea levels in serum, but the other parameters mentioned above were not sig-
niﬁcantly modiﬁed as compared to the values in nontreated rats. Taking into account these results, we conclude that chronic CDDP
administration induces also severe nephrotoxicity, in contrast to CDDP acute application, without any signiﬁcant modiﬁcation in
the activity of relevant antioxidant enzymes such as superoxide dismutase and glutathione peroxidase, renal glutathione and lipid
peroxides, by which the role of the antioxidant system in chronic nephrotoxicity induced by CDDP in rats is uncertain.
INTRODUCTION
Cisplatin(cis-diamminedichloroplatinum II) (CDDP)
is one of the most potent antitumor drugs [1]. High doses
of CDDP produce the impairment of kidney function,
which is recognized as the main side-eﬀect and the
most important dose-limiting factor [2]. The alterations
inducedbyCDDPinthekidneyfunctionswerecharacter-
ized by signs of injury, such as changes in urine volume,
body weight, in glutathione status, increase of products
of lipid peroxidation, and changes in creatinine clearance
[3]. Histologically, the acute toxic tubular necrosis
observed after CDDP administration is similar to that
produced in intoxication by mercury or cadmium [4]
suggesting that CDDP nephropathy may be attributable
ultimately to the toxicity of the platinum molecules which
induce damage in the proximal tubular cells.
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CDDP is able to generate reactive oxygen species
(ROS) such as superoxide anion and hydroxyl radical
[5, 6, 7] and to inhibit the activity of antioxidant en-
zymes in renal tissue [8]. Furthermore, glutathione de-
pletion and increase of thiobarbituric acid-reactive sub-
stances (TBARS) induced by CDDP were found and they
are determinant steps in oxidative stress in the kidney tis-
sue, which leads to nephrotoxicity [9]. However, in con-
trast to the former studies on acute nephrotoxicity in-
duced by CDDP in rats, little has been done to investigate
the role of ROS in the development of chronic nephrotox-
icity induced in rats by this drug [10].
Taking into account that in human beings CDDP
chemotherapy is carried out at doses in which the anti-
tumor agent is already nephrotoxic (higher than 2mg/kg)
and that more than one cycle of drug administration is
necessary to obtain eﬀective results against solid tumors,
we decided to investigate the behavior of the antioxidant
enzymes superoxide dismutase (SOD) and glutathione
peroxidase (GSH-Px), the lipid peroxides and the glu-
tathione (GSH) content in kidney homogenates from rats
submitted to CDDP-induced chronic nephrotoxicity.140 Ricardo Gonz´ alez et al 2005:3 (2005)
MATERIALS AND METHODS
Chemicals
Serum creatinine and urea were measured spec-
trophotometrically with assay kits purchased from the
Carlos J Finlay, Biological Products Enterprise Havana,
Cuba. All reagents used in determinations of GSH,
SOD, GSH-Px, thiobarbituric acid-reactive substances
(TBARS), and CDDP were purchased from Sigma Chem-
icals (St Louis, Mo). Other reagents of analytical grade
were obtained from normal commercial sources.
Animalsandtreatments
Male Sprague-Dawley rats (200–250g) were used in
theexperiment.TheanimalswerepurchasedfromtheNa-
tional Center for Laboratory Animal Production (CEN-
PALAB, Havana, Cuba), housed in an environmentally
(t = 25◦C) and air humidity (60%) controlled room
with a 12-hour light-dark cycle, and kept on a standard
laboratory diet and drinking water ad libitum. The ex-
periments were conducted in accordance with the ethi-
cal guidelines for investigations in laboratory animals and
were approved by the Ethical Committee for Animal Ex-
perimentation of the National Center for Scientiﬁc Re-
search (CNIC).
Two groups of eight rats were used in the experiment:
one control group without treatment, and one group re-
ceiving 1mg/kg of CDDP twice weekly for 10 weeks as it
wasreportedbyChoieetal[4].CDDPwasinjectedIPand
was dissolved in physiologic saline (1mg/mL) within one
hour before use. One week after ending the treatment pe-
riod, blood was collected from the posterior cava vein in
each animal, under ether anesthesia, to determine serum
levels of blood urea and creatinine using assay kits. The
kidneys were removed and used, one of them for bio-
chemical assays and the other one for histopathological
examination.
Biochemicalassays
Kidney homogenates were obtained using a tissue ho-
mogenator Ultraturrax T-25 Polytron at 4◦C. The ho-
mogenates (1:10w/v) were prepared by using a 100mM
KCl buﬀer (pH 7) containing EDTA 0.3mM(buﬀer 1),
for GSH, TBARS, GSH-Px, and SOD determinations. All
homogenates were centrifuged at 600g for 60 minutes at
4◦C and the supernatants were used for biochemical as-
says.
DeterminationofGSHcontent
GSH was determined spectrophotometrically by a
slightly modiﬁed version of the method of Beutler et al
[11]. One mL of the kidney homogenate, as described be-
fore, was mixed with 1.5mL of 5% metaphosphoric acid
and centrifuged at 3000g for 10 minutes at room temper-
ature. Five hundred microliters of this acidic supernatant
was mixed with 2mL of 0.2M phosphate buﬀer and
0.25mL of 0.04% 5,5 -dithiobis(-2-nitrobenzoic acid).
Absorbance of the yellow solution was measured at
412nm within 10 minutes. A molar extinction coeﬃcient
(13.6Mcm −1) that describes the formation of the thio-
late anion by the reaction of sulfhydryl groups with 5,5 -
dithiobis-2-nitrobenzoic acid (DTNB) at 412nm was
used to quantify GSH.
DeterminationofSODactivity
The SOD activity was determined by a modiﬁed ver-
sion of the method of Minami and Yoshikawa [13]. Fifty
microliters of the kidney homogenate was mixed with
450µL of cold deionized water, 125µL of chloroform, and
250µL of ethanol. The mixture was centrifuged at 8000g
for 2 minutes at 4◦C. Five hundred microliters of the ex-
tract was added to the reaction mixture containing 500µL
of 72.4mM tris-cacodylate buﬀer with 3.5mM diethy-
lene pentaacetic acid (pH 8.2), 100µL of 16% TritonX-
100, and 250µLo f0 .9mM nitroblue tetrazolium (NBT).
The reaction mixture was incubated for 5 minutes at
37◦C before adding 10µL of 9mM pyrogallol (dissolved
in10mMHCL).Then,itwasincubatedforexactly5min-
utes at 37◦C. The reaction was stopped with the addition
of 300µLo f2Mf o r m i cb u ﬀer (pH 3.5) containing 16%
TritonX-100. The absorbance was measured at 540nm in
thespectrophotometer.OneunitofSODenzymaticactiv-
ity is equal to the amount of enzyme that diminishes the
initial absorbance of nitroblue tetrazolium by 50%.
DerterminationofGSH-Pxactivity
GSH-Pxwasmeasuredusingamodiﬁedversionofthe
method of Faraji et al [14]. All reaction mixtures were
dissolved in 20mM sodium phosphate buﬀer containing
6mM EDTA (pH 7.0). The reaction mixture consisted
of 98.8µL of phosphate buﬀer, 700µLo f2 .86mM GSH,
100µL of 1mM sodium azide, 100µL of 1mM NADPH,
and 4.2µLo fG S Hr e d u c t a s e( 0 .5 units). Then, 10µLo f
the tissue homogenate supernatant was added to the re-
action mixture and incubated at room temperature for
10–15 minutes. Afterward, 10µL of 30mM t-butyl hy-
droperoxide (dissolved in bidistilled water) was added to
the reaction mixture and measured at 340nm for 7 min-
utes in the spectrophotometer. A molar extinction coeﬃ-
cient of 6.22 × 103 Mc m −1 was used to determine the ac-
tivity of GSH-Px. The enzyme activity is expressed as in-
ternational units of enzymatic activity/mg of protein. In-
ternational units are expressed as µmol of hydroperoxides
transformed per min/mL of enzyme.
Lipidperoxidationassay
This assay is used to determine thiobarbituric acid-
reactivesubstances(TBARS)levelasdescribedbyOhkawa
et al [12]. Two hundred microliters of tissue homogenate
supernatant was added to 100µLo fs o d i u md o d e c y ls u l -
fate (SDS), 750µL of 20% acetic acid (pH 3.5), 750µL
of 0.6% thiobarbituric acid, and 300µL of distilled water
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Table 1. Nephrotoxicity after chronic treatment with CDDP. Rats were injected IP with CDDP (1mg/kg) twice weekly for 10 weeks
and sacriﬁced one week after the last dose. Values are means ± SD. N = 8. ∗ denotes that P<. 05.
Group Body weight (g) Creatinine (µM) Urea (mM)
Mean ± SD Mean ± SD Mean ± SD
Control 474.5 ±93.9 113.4 ±4.96 .6 ± 0.64
CDDP (1 mg/kg) 417.2 ±37.8 281.2 ±45.4∗ 39.1 ±19.9∗
Table 2. Antioxidant status of rat kidney after chronic treatment with CDDP. Each value represents mean ± SD of eight animals.
TBARS SOD GSH GSH-Px
Group (nmol/mg prot) (U/µg prot) (nmol/mg prot) (UI/mg prot)
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Control 0.3 ±0.08 7.4 ±0.99 8.8 ±1.68 12.2 ±2.61
Cisplatin (1mg/kg) 0.3 ±0.08 8.7 ±1.70 8.9 ±1.50 9.8 ±2.02
were allowed to cool at room temperature. Then 2.5mL
of butanol: pyridine (15:1) and 500µL of distilled wa-
ter were added, vortexed, and centrifuged at 2000g for
15 minutes. The absorbance of 3 mL of the colored layer
was measured at 532nm spectrophotometrically using
1,1,3,3-tetraethoxypropane as a standard.
Proteinassay
Protein concentrations were determined by the
method of Lowry [15] using bovine serum albumin as a
standard.
Histopathologicalexamination
The left kidneys were quickly removed and ﬁxed
for 2 hours in a solution containing 150mL ethanol,
60mL formaldehyde, 15mL acetic acid, and 1g picric
acid. Thereafter the samples were included in phosphate-
buﬀered formaldehyde until they were embedded in
paraﬃn, sectioned at 3µm, stained with hematoxylin and
eosin (H/E), and evaluated by light microscopy.
Statisticalanalysis
Statistical analysis was performed using analysis of
variance (ANOVA). Diﬀerences between treatments were
determined by the Mann-Whitney test. The results were
expressed as the mean ± S Do fe i g h tv a l u e si ne a c hg r o u p
and a statistical probability of P<. 05 was considered to
be signiﬁcant.
RESULTS
Table 1 shows the changes in serum creatinine, blood
urea nitrogen, and body weight after chronic treatment
withCDDPduring10weeks.InCDDP-administeredrats,
serum creatinine and urea concentrations were increased
signiﬁcantly above those of control rats. Mean urea level
was about 5.9-fold higher in the CDDP (P<. 001) group
compared to the control group, and creatinine was in-
creased about 2.4-fold (P<. 001). Body weight of animals
treated with CDDP was slightly lower than that of con-
trols, but this decrease was not statistically signiﬁcant.
Figure 1. Normal histological structure of rat kidney. HE 250X.
Table 2 shows antioxidant status of rat kidney after
chronic treatment with CDDP. SOD and GSH values were
not signiﬁcantly modiﬁed with respect to those of control
rats. TBARS, which indicate the extent of lipid peroxida-
tion, also remained unchanged in the kidney of animals
chronically treated with CDDP. The GSH-Px activity was
little decreased in the CDDP group, but this decrease was
not statistically signiﬁcant.
The toxic eﬀect of chronic CDDP administration was
conﬁrmed by the detection of morphologic alterations in
kidney slices of treated animals. Figure 1 shows the nor-
mal histological feature of a kidney belonging to a non-
treated control rat.
The kidneys of rats chronically treated with CDDP
wereenlargedandthesurfacewasmarkedlygranular.His-
tologically, the most characteristic feature was massive
tubulardilationinthecorticomedullaryregionandalsoin
thecorticalareaaccompaniedwithﬂatteningandnecrosis
of tubular epithelial cells (Figure 2). Also, mononuclear
cellinﬁltrationandinterstitialﬁbrosisbetweenthedilated
t u b u l e sw e r eo b s e r v e d( Figure 3).
DISCUSSION
Using an experimental model of CDDP-induced
chronic nephrotoxicity in rats, we evaluated the renal ac-
tivity of the key antioxidant enzymes (SOD, GSH-Px), the
glutathione level and TBARS content of tissue as an index
of lipid peroxidation.142 Ricardo Gonz´ alez et al 2005:3 (2005)
Figure 2. Massive tubular dilation accompanied with ﬂattening
and necrosis of tubular epithelial cells in kidney of rat chroni-
cally treated with CDDP. HE 250X.
Figure 3. Mononuclear cell inﬁltration and interstitial ﬁbrosis
between the dilated tubules in kidney of rat chronically treated
with CDDP. HE 250X.
Our results demonstrated that repeated treatment
with CDDP (1mg/kg, intraperitoneally, twice weekly) for
10 weeks induced biochemical and histological signs of
renal injury (Table 1, Figures 2 and 3) without any sig-
niﬁcant reduction in the activity of SOD and GSH-Px.
Neither GSH nor lipid peroxides levels were signiﬁcantly
modiﬁed in this chronic model of renal failure (Table 2).
However, several studies demonstrated that CDDP-
induced acute nephrotoxicity is mediated by depletion of
renal GSH and by impaired activity of SOD and GSH-Px
as well as an increase in renal lipid peroxidation [16, 17,
18, 19, 20]. In relation to renal GSH levels, whereas some
reports show GSH depletion in acute CDDP nephrotoxic-
ity, others show increased or normal GSH levels under the
same experimental conditions. According to Meyer and
Madias [2] these observations are not necessarily contra-
dictory; they may represent diﬀerent stages of the toxic
response to CDDP.
On the other hand, a possible explanation for the ab-
sence of changes in most of the antioxidant/oxidant pa-
rameters measured in the rat kidney may be an adapta-
tion to the continuous stress induced by treatment with
low doses of CDDP.
Trachtman et al [10] examined whether there is in-
creased production of ROS during chronic renal fail-
ure induced in rats subjected to 3/4 nephrectomy three
weeks after surgery. This study revealed no detectable
renal production of ROS in rats with chronic renal fail-
ure. Thus, the role of lipid peroxidation and its position
in the chain of events that leads to CDDP nephrotoxic-
ity still remains controversial. However, Kruidering et al
[21] have suggested that although free-radical generation
is not the direct cause of cisplatin-induced renal injury, it
may contribute to CDDP nephrotoxicity, since the in vivo
administration of antioxidants to animals can attenuate
or inhibit the renal damage.
Also induction of heme oxygenase-1 (HO-1) is
thought to serve as an immediate protective response
against the nephrotoxicity of CDDP. Heme oxygenase
(HO) catalyzes the ﬁrst and rate-limiting step in the
degradation of heme to biliverdin and bilirubin, respec-
tively. Several studies have ascribed the protective eﬀect of
HO activity against oxidative-stress-related toxicity to in-
creased levels of bilirubin [22]. Its HO-1 isoenzyme is a
widely distributed heat-shock protein and is induced by a
variety of stimuli, including UV irradiation, heavy met-
als, inﬂammation, and pro-oxidant states [23]. The as-
sumption that HO may serve as a safeguard of cellular
redox levels concurs with the reports describing the ﬁrst
case of human hereditary HO-1 deﬁciency showing the
important role of HO-1 in protecting the kidney against
chronic low-level oxidative insult [24]. Moreover, stud-
ies using transgenic mice deﬁcient in HO-1 (-/-) showed
that absence of HO-1 resulted in more severe renal failure
and greater renal injury as compared to wild-type mice
treated with CDDP. Furthermore, increased HO activity
was shown to protect against the nephrotoxicity of CDDP
in rats while inhibition of HO exacerbated its toxic eﬀect
[25, 26]. Currently research is in progress in our labora-
tory in order to elucidate the modulation of this inducible
enzyme in the course of chronic renal nephrotoxicity in-
duced by CDDP.
Taking into account the results of this study, we can
conclude that chronic CDDP administration produces se-
verenephrotoxicityinratswithoutanysigniﬁcantmodiﬁ-
cation in the activity of endogenous antioxidant enzymes,
renal GSH and lipid peroxides. Further studies are needed
to clarify whether the antioxidant enzymes within the rat
kidneys can be modulated in CDDP-induced chronic re-
nal failure and, if so, how it will be relevant in the early
course of chronic renal failure.
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